


Curriculum Vitae

Name	Seock-Ah IM	
Current Position & Affiliation	Department of Internal Medicine Seoul National University Hospital	
Country	Korea	
Educational Background		

1996 ~ 1999	Ph.D. Ewha Womans University, College of Medicine, Seoul, Korea
1993 ~ 1995	M.S. Ewha Womans University, College of Medicine, Seoul, Korea
1985 ~ 1991	M.D. Ewha Womans University, College of Medicine, Seoul, Korea

Professional Experience

2019.7 ~ present	Director, Cancer Research Institute, Seoul National University
2003.9 ~ present	Professor, Assistant Professor, Associate Professor Department of Internal Medicine, Seoul National University, College of Medicine
2008.3 ~ 2009.2	Translational Research Scientist, AstraZeneca Oncology R&D center, Cheshire, UK
2007.3 ~ 2010.2	Korean Cancer Study Group AstraZeneca Oncology Fellowship
2000.1 ~ 2003.8	Instructor, Assistant Professor, Department of Internal Medicine, Ewha Womans University, College of Medicine

- 1997.3 ~ 1998.9 Research Fellow at Division of Internal Medicine,
Department of Neuro-Oncology,
M.D. Anderson Cancer Center, Houston, Texas, USA
- 1996.3 ~ 1997.2 Clinical Fellowship, Division of Hemato-oncology,
Department of Internal Medicine,
Seoul National University Hospital

Main Scientific Publications

1. Overall Survival with Ribociclib plus Endocrine Therapy in Breast Cancer. *N Engl J Med.* 2019 Jul 25;381(4):307-316.
2. Palbociclib plus exemestane with gonadotropin-releasing hormone agonist versus capecitabine in premenopausal women with hormone receptor-positive, HER2-negative metastatic breast cancer (KCSG-BR15-10): a multicentre, open-label, randomised, phase 2 trial. *Lancet Oncol.* 2019 Oct 24. S1470-2045(19)30565-0
3. Profiling of protein-protein interactions via single-molecule techniques predicts the dependence of cancers on growth-factor receptors. *Nat Biomed Eng.* 2018 Apr;2(4):239-253
4. A phase II trial of the pan-HER inhibitor poziotinib, in patients with HER2-positive metastatic breast cancer who had received at least two prior HER2-directed regimens: results of the NOV120101-203 trial, *Int J Cancer*, 143(12):3240-3247, 2018
5. Olaparib for Metastatic Breast Cancer in Patients with a Germline BRCA Mutation, *The New England journal of medicine*, 377(6):523-533, 2017